<DOC>
	<DOCNO>NCT02448095</DOCNO>
	<brief_summary>This observational study aim assess tolerability safety profile Ponatinib , drug use Chronic Myeloid Leukemia patient Philadelphia positive . This drug use chronic phase disease , accord Italian national compassionate law 648/96 .</brief_summary>
	<brief_title>Retrospective Evaluation CML Patients National Compassionate Program</brief_title>
	<detailed_description>This observational study aim assess tolerability safety profile Ponatinib , drug use Chronic Myeloid Leukemia patient Philadelphia positive . This drug use chronic phase disease , accord Italian national compassionate law 648/96 .</detailed_description>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Ponatinib</mesh_term>
	<criteria>CML Ph+ patient chronic phase 18 year old old Patients receive either Dasatinib Nilotinib result resistant tolerant drug develop T3151 mutation Patients start Ponatinib least 12 month registration Informed consent sign registration CML Ph+ patient accelerate blast phase acute lymphoblastic leukemia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Chronic myeloid leukemia</keyword>
	<keyword>Philadelphia positive</keyword>
	<keyword>Compassionate use</keyword>
</DOC>